Glabellar Lines Clinical Trial
Official title:
A Phase 3, Multicenter, Open-label Study to Evaluate the Safety of AGN-151586 for the Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to evaluate the safety of AGN-151586 over multiple repeat treatments of the study drug to improve the appearance of glabellar lines. AGN-151586 is an investigational product being developed for the treatment of GL. Around 940 to 1100 adult participants with moderate to severe GL will be enrolled in the study in approximately 45 sites in the United States. This is an open-label, 126 day study in which all participants will receive 5 intramuscular AGN-151586 injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may receive up to 2 additional cycles of treatment during the study. Participants will attend regular visits during the study at a study site. The effect of the treatment will be checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04096326 -
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
|
Phase 2 | |
| Completed |
NCT02961673 -
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT01271452 -
Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
|
Phase 4 | |
| Completed |
NCT05013424 -
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
|
Phase 2 | |
| Completed |
NCT01189760 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
|
Phase 3 | |
| Completed |
NCT05100199 -
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
|
Phase 2 | |
| Completed |
NCT03721016 -
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
|
Phase 3 | |
| Completed |
NCT04157686 -
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
|
Phase 3 | |
| Completed |
NCT02353897 -
Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
|
||
| Completed |
NCT03732833 -
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
|
Phase 3 | |
| Completed |
NCT06212960 -
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
|
Phase 1 | |
| Completed |
NCT05089357 -
Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
|
||
| Completed |
NCT00408785 -
A Study Of BOTOX For The Treatment Of Glabellar Lines
|
Phase 3 | |
| Completed |
NCT05380154 -
Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.
|
Phase 3 | |
| Completed |
NCT01224015 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
|
Phase 3 | |
| Completed |
NCT05248880 -
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
|
Phase 3 | |
| Completed |
NCT03216408 -
Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Recruiting |
NCT06308198 -
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
|
Phase 3 | |
| Completed |
NCT05298449 -
Phase 2 of HU-045 in Glabellar Lines
|
Phase 2 | |
| Not yet recruiting |
NCT06246552 -
Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines
|
Phase 2 |